Oncolytic Viruses and Novel Biologic Therapies

Oncolytic viruses are engineered or naturally occurring viruses that selectively infect and kill cancer cells while sparing normal tissue. They stimulate antitumor immune responses and can be combined with immunotherapy for enhanced efficacy. Talimogene laherparepvec (T-VEC) is an FDA-approved oncolytic virus for melanoma. Novel biologic therapies also include monoclonal antibodies, bispecific T-cell engagers, and fusion proteins, which harness the immune system to recognize and attack tumors. These therapies represent a shift toward precision immunotherapy, offering new hope for hard-to-treat cancers. Ongoing trials aim to refine delivery, enhance tumor specificity, and minimize immune-related side effects.

    Related Conference of Oncolytic Viruses and Novel Biologic Therapies

    September 07-08, 2026

    26th World Congress on Cancer and Diagnostics

    Paris, France
    September 28-29, 2026

    36th Experts Meet On Cancer Research & Therapy

    Aix-en-Provence, France
    October 05-06, 2026

    22nd International Conference on Cancer Research

    Madrid, Spain
    November 19-20, 2026

    44th World Cancer Conference

    Dubai, UAE
    November 23-24, 2026

    8th International Conference on Women Oncology

    Miami, USA
    November 23-24, 2026

    7th Cancer Diagnostics & Treatment Conference

    Miami, USA
    November 24-25, 2026

    6th International Conference on Oncology and Cancer

    Paris, France
    December 03-04, 2026

    10th Global Meeting on Oncology and Radiology

    Madrid, Spain
    December 08-09, 2026

    14th Euro Breast Cancer and Therapeutics

    Paris, France
    December 08-09, 2026

    27th World Congress on Cancer Summit

    Paris, France
    February 15-16, 2027

    5th World Congress on Oral Cancer

    Singapore City, Singapore
    April 15-16, 2027

    12th World Conference on Breast and Cervical Cancer

    Amsterdam, Netherlands

    Oncolytic Viruses and Novel Biologic Therapies Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in